Citi raises CSL's PT after $1.6 billion Alentis deal

CSL

07/10/2026 19:43

** Citi raises PT of Australia's CSL CSL.AX to A$180, sees upside in deal with Alentis 
** On Monday, the biotech giant signed an agreement with Swiss drugmaker Alentis Therapeutics to co-develop and co-promote treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion
** Brokerage says the deal is consistent and structurally sound aligning with company commentary
** Says deal sticks within an area CSL already operates - orphan renal conditions
** Sees $125 million risk adjusted sales by 2031, addresses that pipeline replenishment is a key concern for investors and sees this as a positive step
** 10 of 17 analysts rate the stock "buy" or higher, seven "hold"; their median PT is A$182, LSEG-compiled data shows
** YTD, stock up nearly 5.5%, as of last close

 (Reporting by Aamir Sheik Khalid in Bengaluru)
 ((Aamir.SheikKhalid@thomsonreuters.com))